NRAS Mutations May Require Mutation-Guided Combination Therapies

Mutant NRAS has remained difficult to target in cancer. New findings suggest that its signaling partnership with wild-type HRAS may offer a targetable vulnerability, but effective strategies may need to be tailored to the specific NRAS mutation.

The post NRAS Mutations May Require Mutation-Guided Combination Therapies appeared first on GEN - Genetic Engineering and Biotechnology News.